The use of crude cartilage for the treatment of human cancers remains a sub
ject of controversy. In this brief commentary, we reviewed the current know
ledge on the anticancer properties of cartilage. We then presented the prop
erties of AE -941, a novel standardized water-soluble extract derived from
shark cartilage that represents less than 5% of the crude cartilage. It is
a multifunctional antiangiogenic product that contains several biologically
active molecules. AE -941 is one of the few antiangiogenic drugs that is u
nder phase III clinical investigation. It is currently evaluated in Europe
and North America for the treatment of refractory renal cell carcinoma and
in North America for metastatic non small cell lung cancer.